Y Intercept Hong Kong Ltd reduced its stake in Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 47.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,950 shares of the company's stock after selling 7,966 shares during the period. Y Intercept Hong Kong Ltd's holdings in Akero Therapeutics were worth $249,000 at the end of the most recent reporting period.
Several other large investors have also recently added to or reduced their stakes in AKRO. Mirae Asset Global Investments Co. Ltd. increased its holdings in Akero Therapeutics by 21.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,511 shares of the company's stock valued at $71,000 after purchasing an additional 446 shares in the last quarter. Summit Financial Wealth Advisors LLC acquired a new stake in Akero Therapeutics in the 3rd quarter valued at $205,000. Victory Capital Management Inc. acquired a new stake in Akero Therapeutics in the 3rd quarter valued at $211,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Akero Therapeutics in the 3rd quarter valued at $265,000. Finally, XTX Topco Ltd acquired a new stake in Akero Therapeutics in the 3rd quarter valued at $308,000.
Akero Therapeutics Stock Down 3.5 %
Shares of AKRO stock traded down $1.55 during trading hours on Friday, hitting $42.12. 947,726 shares of the company were exchanged, compared to its average volume of 851,527. The company has a debt-to-equity ratio of 0.05, a quick ratio of 17.25 and a current ratio of 17.25. Akero Therapeutics, Inc. has a one year low of $17.86 and a one year high of $58.40. The business's 50-day simple moving average is $40.49 and its two-hundred day simple moving average is $33.19. The stock has a market capitalization of $2.94 billion, a price-to-earnings ratio of -11.23 and a beta of -0.19.
Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last issued its quarterly earnings results on Friday, February 28th. The company reported ($0.99) EPS for the quarter, missing the consensus estimate of ($0.98) by ($0.01). Sell-side analysts predict that Akero Therapeutics, Inc. will post -3.99 EPS for the current fiscal year.
Insider Transactions at Akero Therapeutics
In other Akero Therapeutics news, insider Timothy Rolph sold 4,818 shares of the firm's stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $30.91, for a total value of $148,924.38. Following the transaction, the insider now owns 178,337 shares of the company's stock, valued at $5,512,396.67. This trade represents a 2.63 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, COO Jonathan Young sold 2,503 shares of the firm's stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $30.79, for a total transaction of $77,067.37. Following the completion of the transaction, the chief operating officer now directly owns 203,783 shares in the company, valued at $6,274,478.57. This represents a 1.21 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 237,492 shares of company stock valued at $11,357,578. Insiders own 7.94% of the company's stock.
Analyst Upgrades and Downgrades
Several analysts recently issued reports on the company. Bank of America upgraded Akero Therapeutics from a "neutral" rating to a "buy" rating and increased their price target for the company from $35.00 to $63.00 in a report on Thursday, January 30th. HC Wainwright raised their target price on Akero Therapeutics from $72.00 to $75.00 and gave the company a "buy" rating in a research note on Monday, March 3rd. UBS Group raised their target price on Akero Therapeutics from $42.00 to $109.00 and gave the company a "buy" rating in a research note on Friday, January 31st. Canaccord Genuity Group raised their target price on Akero Therapeutics from $56.00 to $73.00 and gave the company a "buy" rating in a research note on Tuesday, January 28th. Finally, Morgan Stanley raised their target price on Akero Therapeutics from $46.00 to $96.00 and gave the company an "overweight" rating in a research note on Tuesday, January 28th. Nine equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of "Buy" and an average target price of $76.29.
Check Out Our Latest Analysis on AKRO
Akero Therapeutics Company Profile
(
Free Report)
Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.
Further Reading
Before you consider Akero Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Akero Therapeutics wasn't on the list.
While Akero Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
